Press releases

November 04, 2025

Ultragenyx Reports Third Quarter 2025 Financial Results and Corporate Update

Read more

November 04, 2025

Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $400 Million to OMERS Life Sciences

Read more

October 30, 2025

Ultragenyx Announces First Patient Dosed in Aurora Study Evaluating GTX-102 in Additional Angelman Syndrome Genotypes and Age Groups

Read more

October 28, 2025

Ultragenyx to Host Conference Call for Third Quarter 2025 Financial Results and Corporate Update

Read more

October 24, 2025

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Read more

October 03, 2025

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Read more

September 30, 2025

Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President

Read more

September 19, 2025

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Read more

September 08, 2025

Ultragenyx Announces Positive Longer-term Data from Phase 3 Study of DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)

Read more

August 29, 2025

Ultragenyx to Participate at Investor Conferences in September

Read more